Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryon Johnson

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Blood Advances|February 3, 2026
TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONLyndsey Runaas, Salena Fank, Katie Palen, et al.
Frontiers in Immunology|December 26, 2022
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell diseaseYaya Chu, Julie-An Talano, Lee Ann Baxter-Lowe, et al.
Haematologica|January 21, 2018
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract diseaseWilliam R Drobyski, Aniko Szabo, Fenlu Zhu, et al.
The Journal of Infectious Diseases|December 30, 2022
Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T LymphocytesYaya Chu, Jordan Milner, Margaret Lamb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Blood Advances|February 3, 2026
TIDRAKIZUMAB FOR THE PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONLyndsey Runaas, Salena Fank, Katie Palen, et al.
Frontiers in Immunology|December 26, 2022
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell diseaseYaya Chu, Julie-An Talano, Lee Ann Baxter-Lowe, et al.
Haematologica|January 21, 2018
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract diseaseWilliam R Drobyski, Aniko Szabo, Fenlu Zhu, et al.
The Journal of Infectious Diseases|December 30, 2022
Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T LymphocytesYaya Chu, Jordan Milner, Margaret Lamb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401David J Chung, Nina Shah, Juan Wu, et al.
Pageof 3